THE PREVALENCE OF MACULAR OEDEMA AND RELATED FACTORS AT TYPE 2 DIABETIC PATIENTS IN CAN THO CITY

Chi An Le1, Van Truyen Ngo1, , Quang Binh Hoang2
1 Can Tho University of Medicine and Pharmacy
2 Can Tho Eye, Dental and Maxillofacial Hospital

Main Article Content

Abstract

Background: Diabetic macular edema and diabetic retinopathy are common microvascular complications in diabetic patients. Numerous studies have shown that macular edema is a major cause of vision loss and vision impairment in diabetic patients. Early detection and timely treatment of macular edema is an effective strategy for preventing vision loss in diabetic patients and improving their quality of life. Objectives: This study investigates the prevalence of diabetic macular edema and diabetic retinopathy, and some related factors in type 2 diabetic patients. Materials and methods: This prospective descriptive, cross-sectional study with analytical components was conducted on 120 diabetic patients with ocular complications in Can Tho City, from June 2025 to January 2026. All patients were screened for macular edema and diabetic retinopathy using Optical Coherence Tomography. Macular edema is defined as retinal thickening of 500 µm within two optic disc diameters from the macula. Results: Diabetic macular edema accounts for 25.8% (31 patients), while diabetic retinopathy accounts for 54.2% (65 patients). Diabetic macular edema is associated with a duration of diabetes exceeding 10 years, hypertension, blood glucose levels, and HDL levels. Conclusion: Macular edema can cause blindness. Attention should be paid to macular edema in diabetic patients with a duration of diabetes exceeding 10 years, especially those with poorly controlled blood glucose, blood pressure, and lipid disorders. To prevent macular edema and diabetic retinopathy, and to slow disease progression, good management of blood glucose, blood pressure, and cholesterol is essential. 

Article Details

References

1. Nguyễn Phước Hải, Nghiên cứu đặc điểm lâm sàng, cận lâm sàng phù hoàng điểm do đái tháo đường tại Bệnh viện Mắt Trung ương. Luận Văn Chuyên Khoa Cấp II.Trường Đại học Y Hà Nội. 2020.
2. Andrew Callan.VEGF in Diabetic Retinopathy and Age-Macular Degeneration, International Journal of Molecular Sciences. 2025. 26(11), 4992, doi: 10.3389/fendo.2025.1710376.
3. Arvind Kumar,Prevalence of diabetes in India: A review of IDF diabetes atlas 10th edition, Current diabetes reviews. 2024. 20(1), e130423215752, doi: 10.2174/1573399819666230413094200.
4. Nurul Athirah Naserrudin, et al. Diabetic retinopathy among type 2 diabetes mellitus patients in Sabah primary health clinics – Addressing the underlying factors, Plos One. 2022. 17(1), 6, doi.org/10.1371/journal.pone.0261249.
5. Hiromi Ohara. Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept, Medicina Kaunas. 2023. 59(6), 1125, doi: 10.3390/medicina59061125.
6. Fernando M Penha.Review of real evidence of dual inhibition of VEGF with faricimab in NAMD and DME.Int J Retina Vitreous. 2024. 10(1), 5, doi: 10.1186/s40942-024-00525-9.
7. Huỳnh Thanh Hùng,Tầm soát phù hoàng điểm bệnh nhân Đái tháo đường típ 2 bệnh viện Nguyễn Tri Phương.Luận Văn Bác sĩ Nội Trú. Đại Học Y Dược Thành Phố Hồ Chí Minh, 2017.
8. Pichi, El Ghrably, I., Agarwal, A., Ghazi.Switch to faricimab after initial treatment with aflibercept with diabetic macular edema. Int Ophthalmol. 2024. 44(1), 275, doi: 10.1007/s10792-024-03226-2.
9. Seema KS, et al. Effect of glycemic control on diabetic retinopathy and diabetic macular edema: A prospective observational study. International Journal of Advances in Medicine. 2021, 177182, doi: 10.18203/2349-3933.ijam20210011.
10. Muhidini Huud Swalehe. Abnormal Lipid Profiles as Markers of Diabetic Macular Edema Among Patients with Type 2 Diabetes Mellitus Attending a Tertiary Hospital in Northern Tanzania: One Year CrossSectionalStudy. MedRxiv. 2026. doi: 10.64898/2026.03.03.26347512.